Company / Operating Cash Flow
Biogen Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$2.2B
FY2025
5-year range
$1.4B / $3.6B
FY2021-FY2025
Trend
-23.3%
vs FY2024
Sector context
#15 of 214
Health Care
What the data says
Among 214 Health Care companies, Biogen is in the top 7% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $1.4B in FY2022 to $7.1B in FY2019.
Based on SEC 10-K filings.
$2.2B in FY2025 with a 5-year CAGR of -12.2%. Top quartile in the Health Care sector.
Improved from $1.5B to $2.2B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +16.8%
- 5-Year CAGR
- -12.2%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 214This company $2.2B Sector average $663.6M
▼
+232.2% above sector average
Key checks
Key Insights
- 5-year CAGR of -12.2%, indicating a declining trend.
- In FY2025, operating cash flow decreased 23.3% year-over-year.
- Ranks #15 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.2B | -23.3% |
| FY2024 | $2.9B | +85.9% |
| FY2023 | $1.5B | +11.8% |
| FY2022 | $1.4B | -62.0% |
| FY2021 | $3.6B | -13.9% |
| FY2020 | $4.2B | -40.2% |
| FY2019 | $7.1B | +14.4% |
| FY2018 | $6.2B | +36.0% |
| FY2017 | $4.6B | -0.8% |
| FY2016 | $4.6B | +17.0% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026